Transcenta Advances Licensing Deals and Funding Plan to Address Audit DisclaimerTip Ranks·Jul 27 at 06:37 PM06628-4.63%LLY-4.55%
Transcenta Adjusts Board Committees as It Works to Fully Meet HKEX Governance RulesTip Ranks·Jul 27 at 10:08 AM06628-4.63%
Transcenta files board, board committee and disclosure management listPUBT·Jul 27 at 09:54 AM06628-4.63%
Transcenta reverts two Lilly-licensed assets for US$4 million cashPUBT·Jul 7 at 06:23 AM06628-4.63%LLY-4.55%
Transcenta grants 451,500 employee share awards under incentive schemePUBT·Jun 30 at 09:50 AM06628-4.63%
Transcenta appoints Hansen Xu as non-executive director after two independent directors resignPUBT·Jun 30 at 07:25 AM06628-4.63%
TRANSCENTA Ozekibart: Filling the gap in rare cancer treatment, opening up a new blue ocean of commercial value同壁财经·May 25 at 06:31 AM06628-4.63%
Transcenta Gains Boost as Inhibrx’s Ozekibart Data and FDA Filing Strengthen Greater China Cancer FranchiseTip Ranks·May 20 at 06:46 PM06628-4.63%
Transcenta Reports Strong Preclinical Results for LIV1-Targeting ADCs in Breast and Prostate CancersTip Ranks·Apr 22 at 06:10 PM06628-4.63%
Transcenta Narrows Annual Loss on Cost Cuts Despite Revenue DeclineTip Ranks·Mar 30 at 08:20 PM5168200.00%516930-0.82%
Transcenta Advances Dealmaking, Licensing and Financing to Resolve Audit Disclaimer and Bolster LiquidityTip Ranks·Jan 22 at 03:08 AM516500-0.81%159849-0.61%
